sbh_logo-RED_NoBG
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SMCxPRO® Services

SBH Sciences offers bioanalytical services for biomarker and large molecule analysis using the ultrasensitive Single Molecule Counting (SMC ®) Technology. We offer the complete menu of MilliporeSigma SMC ® ultrasensitive biomarker assays as well as custom assay development. The SMCxPRO platform can detect extremely low levels of established disease biomarkers, capturing concentrations down to the femtogram per mL level. This additional sensitivity allows for monitoring small changes in protein concentrations to measure biomarkers associated with disease progression accurately. This could be invaluable in supporting many areas of research, including neurological targets, Pharmacokinetics and Pharmacodynamics (PK/PD), Immunogenicity (ADA), and early oncology targets.

Here Comes Header

SMC® Technology Unique Capabilities

The SMCxPRO ® Technology provides enhanced quantification at both low and high levels of expression. The immunoassay uses traditional ELISA technology, combined with a unique assay elution step. The eluted fluorescently labeled detection antibodies are digitally counted on the SMCxPRO® and the data is computed against a known concentration providing a quantitative measurement of the target analytes in the biological samples such as CSF, serum, and plasma. It is this unique technology that enables the ultrasensitive detection levels.

Here Comes Header

Contact Us

MilliporeSigma SMCTM Assay Offering the analysis of the following Analytes

Key: H=Human; M=Mouse; R=Rat; GP=Guinea Pig; Cy=Cynomolgus Monkey; C=Canine

Analyte

LLoQ 
(pg/mL)1

Standard Curve Range (pg/mL)

Median Endogenous (pg/mL)2

Species3

Sample Types4

Sample volume (μL)

Phospho-α-Synuclein(Ser129)6,7

0.1

0.05-50

P: 2.74
S:  1.81
C:  0.64

H

P,S,C

20, 20, 50

Total-α-Synuclein6,7

1.95

0.49-500

P: 1885
S: 1240
C: 233

H

P,S,C

0.5, 0.5, 10

Phospho-Akt1 (Ser473) 

0.98

1.0-1000

NA

H, M, R

L

varies8

Total Akt1 

7.80

1.0-1000

NA

H, M, R

L

varies8

Amyloid beta 1-406,7 

5.86

2.93-3000

Normal CSF:  1366
P:  152

H, M, R

C, P

5, 25

Amyloid beta 1-426,7 

0.98

0.24-250

Normal CSF:  192
P:  15

H, M, R

C, P

5, 25

BDNF6,7

0.04

0.02-100

P:  783
S:  410
CSF:  0.13

H

C, P, S

100, 1, 1

cTnI 6,7

0.69

0.17-600

P:  3.04
S: 3.02

H, Cy, R, C, GP

P, S

100

G-CSF 

0.08

0.02-20

17

H

P

10

GFAP6,7

0.12

0.06-300

P: 1.91
S: 1.93
C: 42.57

H

C, P, S

3.3, 100, 100

GLP-1 (active) 

0.40

0.05-50

3.46

H, M, R, C

P

100

GLP-1 (total) 

0.39

0.20-200

17.8

H, M, R, C

P

20

Glucagon6,7

0.78

0.20-200

44

H, M, R

P

10

GM-CSF 

0.02

0.005-5

0.2

H

P

100

IFN-α26,7

0.031

0.015-80

P: 0.08
S: 0.08

H

P,S

100

IFN-β1 

0.15

0.07-170

P: 0.35
S: 0.64

H

P,S

50

IFN-γ6,7

0.03

0.016-25

P:  1.4
S:  1.4

H

P, S

25

IL-1α26,7

0.12

0.06-60

P:  0.09
S:  0.10

H

P,S

100

IL-1β6,7

0.20

0.05-50

P:  0.11
S: 0.12

H

P,S

100

IL-2 (new version) 

0.09

0.02-80

0.21

H

P, S

100

IL-21 

0.20

0.11-250

0.53

H

S

50

IL-226,7

0.10

0.05-50

P:  1.51
S:  1.52

H

P,S

25

IL-236,7

0.10

0.1-100

P:  0.65
S:  0.46

H

P,S

100

IL-46,7

0.04

0.01-10

P:  0.18
S:  0.18

H

P,S

100

IL-56,7

0.04

0.05-50

P: 0.37
S:0.30

H

P,S

100

IL-66,7

0.08

0.01-50

P:  0.70
S: 0.69

H

P, S

75

IL-7 

0.39

0.10-100

4.91

H

P, S

50

IL-8 / CXCL8 

0.24

0.24-250

3.6

H

P, S

50

IL-106,7

0.10

0.10-100

P:  0.90
S:  0.89

H

P,S

100

IL-12p706,7

0.05

0.05-50

P:  0.29
S:  0.28

H

P, S

100

IL-136,7

0.04

0.02-100

P:  0.37
S:  0.33

H

P,S

100

IL-15 

0.10

0.02-25

3.38

H

P, S

100

IL-17A/F Heterodimer6,7

1.17

0.60-600

P:  1.36
S:  3.20

H

P,S

50

IL-17A6,7

0.07

0.02-60

P:  0.31
S:  0.30

H

P, S

50

IL-17F6,7

0.20

0.10-100

P:  1.10
S:  1.18

H

P, S

50

IL-186,7

0.09

0.04-100

P: 138
S: 145

H

P,S

10

KIM-15

3.91

1.0-1000

P: 65
S: 75
U: 147

H

P, S, U

25, 25, 5

MCP-16,7

0.15

0.06-400

P: 682
S: 1021

H

P,S

1.56

NGFβ6,7

0.017

0.09-200

P: 1.20
S: 0.92

H

P,S

50

NPTX26,7

0.58

0.29-1000

P: 8268
S: 8161
C: 1677

H

P,S,C

0.1, 0.1, 0.3

Phospho-Tau(Thr181)6,7

0.94

0.23-240

P: 3.4
S: 2.0
C: 21

H

P,S,C

50, 100, 25

Total Tau6,7

2.34

1.17-1200

P: 27.1
S: 7.0
C: 88.91

H

P,S,C

50, 100, 25

TNFα 

0.40

0.05-50

38.6

M

S

25

TNFα6,7

0.20

0.05-50

P:  0.85
S:  0.78

H

P,S

100

TSLP6,7

1.56

0.78-800

P: 5.04
S: 3.86

H

P,S

100

UCHL16,7

2.60

1.30-2000

P: 22.06
S: 20.49
C: 413

H

P,S,C

25,25,5

VEGF-A6,7

0.20

0.10-100

P:  48
S:  50

H

P,S

25

SARS-CoV-2 RBD IgG 

NA9

NA9

NA9

H

P,S

2

SARS-CoV-2 S1 IgA 

NA9

NA9

NA9

H

P,S

2

1 – LLoQ: Lowest point on standard curve that meets the following criteria for all sample types claimed: CV < 20% and accuracy within 20% of expected values, reproducible across at least three assay runs across three different operators.
2 – Median Endogenous: Minimum of 10 samples from individual donors assessed for ability to quantify baseline biomarker values.
3 – Optimized for first species type listed. Other listed species have been tested, but not optimized for peak performance.
4 – Optimized for use in sample type(s) listed. Key: P=Plasma; S=Serum; L=Lysate; U=Urine; C=Cerebrospinal Fluid (CSF)
5 – Plate-based assay
6 – Assay characteristic data is representative for both Erenna® and SMCxPRO™.
7 – Streamlined format kit.
8 – Sample volume varies based on dilution factor selected by user
9 – Qualitative assay